IntelGenx Technologies (IGXT) Stock Price, News & Analysis

Company Overview

IntelGenx Technologies Inc. is a specialty pharmaceutical company headquartered in Montreal, Canada, that focuses on the development and commercialization of novel drug delivery systems. Established to address limitations of traditional oral and injectable formulations, the company’s technology platforms aim to improve patient compliance, enhance bioavailability and provide controlled release profiles for a variety of therapeutic agents.

The core of IntelGenx’s offering lies in its proprietary film-based delivery technologies, including RapidFilm and MucoFilm, which are thin polymer films designed for oral mucosal administration. These films can dissolve quickly or be formulated for sustained release, enabling delivery of small molecules, peptides and other active pharmaceutical ingredients without the need for water or swallowing. In addition, the company is advancing its ProNeura long-acting drug delivery system, an implantable rod designed for sustained release over periods of months to years, with potential applications in chronic disease and hormone therapies.

IntelGenx collaborates with pharmaceutical partners around the world to in-license development candidates and out-license its delivery platforms for late-stage clinical or commercial programs. With strategic alliances spanning North America, Europe and other regions, the company seeks to leverage its manufacturing facility in Cowansville, Québec, to support both clinical supply and commercial production. Led by a management team with extensive experience in formulation science and pharmaceutical product development, IntelGenx continues to advance a pipeline of programs aimed at addressing unmet medical needs and improving patient outcomes.

Key Stats

• Today's Range: $0.17 to $0.17
• 50-Day Range: $0.17 to $0.17
• 52-Week Range: $0.09 to $0.22
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $29.17 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IGXT Stock Analysis - Frequently Asked Questions

How have IGXT shares performed this year?

IntelGenx Technologies' stock was trading at $0.1670 at the beginning of the year. Since then, IGXT stock has increased by 0.0% and is now trading at $0.1670.

How were IntelGenx Technologies' earnings last quarter?

IntelGenx Technologies Corp. (OTCMKTS:IGXT) released its quarterly earnings results on Thursday, November, 12th. The company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.01. The company had revenue of $0.51 million for the quarter.

How do I buy shares of IntelGenx Technologies?

Shares of IGXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of IntelGenx Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that IntelGenx Technologies investors own include Pfizer (PFE), Tesla (TSLA), Advanced Micro Devices (AMD), Ford Motor (F), Rithm Capital (RITM), Rolls-Royce Holdings PLC (RYCEY) and Blink Charging (BLNK).

Company Calendar

• Last Earnings: 11/12/2020
• Today: 9/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:IGXT
• CIK: 1098880
• Web: www.intelgenx.com
• Phone: (514) 331-7440
• Fax: 514-331-0436
• Employees: 38
• Year Founded: 2003

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $1.04 million
• Price / Sales: 28.05
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.07) per share
• Price / Book: -2.39

Miscellaneous

• Outstanding Shares: 174,658,000
• Free Float: 101,214,000
• Market Cap: $29.17 million
• Optionable: Not Optionable
• Beta: 2.47